期刊
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
卷 111, 期 -, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pnpbp.2021.110351
关键词
Type 2 Diabetes Mellitus; Major Depressive Disorder; Pathogenesis; Therapies
资金
- Oswaldo Cruz Foundation of Pernambuco (FIOCRUZ-PE), Research Excellence Program -Aggeu Magalhaes Institute (IAM PROEP) [400208/2019-9]
- Knowledge Generation Program - Oswaldo Cruz Foundation (FIOCRUZ) [VPPCB-007-FIO-18-2-17]
- National Council for Scientific and Technological Development (CNPq) [301777/2012-8]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brasil (CAPES) [001]
- Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM) [465489/2014-1]
Type 2 Diabetes Mellitus and Major Depressive Disorder share common neuroimmune mechanisms, such as neurodegeneration and neuroinflammation. Understanding and addressing depressive symptoms in diabetic patients is crucial for fully addressing the pathophysiology and treatment of T2DM.
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disease with symptoms that go beyond the domain of glucose metabolism. In fact, research has shown that T2DM is accompanied by neurodegeneration and neuroinflammation. Interestingly, Major Depressive Disorder (MDD), a mood disorder characterized mainly by depressed mood and anhedonia is a key feature of T2DM. A body of evidence demonstrates that there are many shared neuroimmune mechanisms underlying the pathophysiology of T2DM and MDD. Therefore, here we review the state-of-art regarding the underlying factors common to both T2DM and MDD. Furthermore, we briefly discuss how depressive symptoms in diabetic patients could be tackled by using novel therapeutic approaches uncovered by these shared mechanisms. Understanding the comorbidity of depression in diabetic patients is essential to fully address T2DM pathophysiology and treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据